Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 199Breast Neoplasms 111Carcinoma, Non-Small-Cell Lung 94Triple Negative Breast Neoplasms 66Neoplasm Metastasis 44Neoplasms 42Lung Neoplasms 25Squamous Cell Carcinoma of Head and Neck 24Esophageal Squamous Cell Carcinoma 18Colorectal Neoplasms 18Stomach Neoplasms 17Adenocarcinoma 17Melanoma 15Head and Neck Neoplasms 15Ovarian Neoplasms 12Cholangiocarcinoma 11Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Gallbladder Neoplasms 10Esophageal Neoplasms 10Carcinoma, Pancreatic Ductal 10Small Cell Lung Carcinoma 9Sarcoma 9Fallopian Tube Neoplasms 9Biliary Tract Neoplasms 9Carcinoma, Squamous Cell 8Neoplasms by Site 7Pancreatic Diseases 6Pancreatic Adenocarcinoma 6Digestive System Neoplasms 6

Interventions

Pemetrexed 3apatinib 2Paclitaxel 2Carboplatin 2tislelizumab 1pembrolizumab 1lenvatinib 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non-squamous Non-small-cell Lung Cancer × 130-nm albumin-bound paclitaxel × Clear all
NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Peking University First Hospital

Phase 2 Not yet recruiting
28 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡